Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move.

Dr. James Hildreth faced the horror of the AIDS epidemic early in his medical career, witnessing the death of an HIV-positive American woman and her newborn baby in the 1980s. The tragedy inspired him to switch his specialty from transplant surgery to HIV research. Dr. Debbie Hagins, a family doctor in Savannah, Ga., also devoted her career to treating HIV, a decades-old public health problem that is drawing renewed attention from Gilead, Merck and other giant drug stocks.

SpaceX Investors Rip $565 Billion Out Of Elon Musk's Hands

Merck Reportedly Goes To Bat In Takeover Battle. But Genomics Stock Reverses.

Chevron Entered The AI Power Business. The Oil Patch Won't Be The Same.

This Once-Deflated Cloud Stock Deserves Another Look. Here's Why.

Today's Spotlight

Jingle bells in July? For a limited time, you can unwrap access to IBD Digital for only $6/month.

Subscribe >

IBD is offering a limited number of tickets to our premier investing workshop––reserve yours now.

Get Your Ticket >

Simple, quick, actionable. Invest like a pro with IBD’s MarketDiem newsletter for only $20/year!

Subscribe>

Investor's Business Daily - a Dow Jones affiliate

IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC.

Sent to: dupa@niepodam.pl

Investor's Business Daily, LLC, PO Box 300, Princeton, NJ 08543-0300

Need help? Have feedback? Feel free to contact us

Terms of Use | Privacy Notice | Manage Subscriptions | Unsubscribe

ID: 7133